Annexon (ANNX) Capital Expenditures (2019 - 2026)
Annexon (ANNX) posted quarterly Capital Expenditures of -$275000.0 for Q1 2026, down 471.62% year-over-year from $74000.0 in Q1 2025, and down 105.32% quarter-over-quarter from $5.2 million in Q4 2025.
Annexon (ANNX) Capital Expenditures (2019 - 2026) Analysis & Trends
Annexon's Capital Expenditures history runs 8 years deep, the most recent figure standing at -$275000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures fell 471.62% year-over-year to -$275000.0; the TTM figure through Mar 2026 stood at $5.0 million (up 1007.59% YoY), while the FY2025 annual figure was $5.3 million, up 35306.67% from the prior year.
- Capital Expenditures for Q1 2026 stood at -$275000.0, down from $5.2 million in the prior quarter.
- The five-year high for Capital Expenditures was $5.2 million in Q1 2022, with the low at -$5.1 million in Q2 2022.
- The 5-year median for Capital Expenditures is $19000.0 (2023), against an average of $380400.0.
- The sharpest annual moves came in 2025 and 2026: Capital Expenditures surged 86133.33% in 2025, then slumped 471.62% in 2026.
- Annexon's Capital Expenditures stood at -$8000.0 in 2022, then jumped by 187.5% to $7000.0 in 2023, then decreased by 14.29% to $6000.0 in 2024, then soared by 86133.33% to $5.2 million in 2025, then tumbled by 105.32% to -$275000.0 in 2026.
- Business Quant data shows ANNX's Capital Expenditures at -$275000.0 in Q1 2026, $5.2 million in Q4 2025, and $48000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -275,000.00 |
| Mar 31, 2026 | -275,000.00 |
| Dec 31, 2025 | 5.17 Mn |
| Dec 31, 2025 | 5.17 Mn |
| Sep 30, 2025 | 48,000.00 |
| Sep 30, 2025 | 48,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Mar 31, 2025 | 74,000.00 |
| Mar 31, 2025 | 74,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Mar 31, 2024 | 361,000.00 |
| Mar 31, 2024 | 361,000.00 |
| Dec 31, 2023 | 7,000.00 |
| Dec 31, 2023 | 7,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Jun 30, 2023 | 162,000.00 |
| Jun 30, 2023 | 162,000.00 |